Work

2022-RA-722-ESGO Phase 2 study assessing the efficacy of adding AL3818 (Catequentinib Dihydrochloride, Anlotinib Hydrochloride) to chemotherapies in subjects with platinum resistant ovarian carcinoma

Year: 2022

Type: article

Study design: Clinical Trial

Source: International Journal of Gynecological Cancer

DOI: 10.1136/ijgc-2022-esgo.552

Authors: David Scott Miller, Matthew Carlson, Jayanthi Lea, Zhe Li, May Gan, Judy Chen, Agustin Garcia, Matthew Schlumbrecht, Matt Pearson, Marilyn Huang

Institutions: The University of Texas Southwestern Medical Center, Advenchen Laboratories, LLC (United States), Louisiana State University, University of Miami, Sylvester Comprehensive Cancer Center

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4312699695

FWCI: 0.211

Cites:

Cited by: 1

Related to: 10